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Abstract
Background The management of multiple long-term medicines of patients with chronic diseases creates a burden for patients. 
However, limited research is performed on its impact on patients’ daily lives. Objective The aim of this study was to explore 
the impact of cardiovascular medication on diferent daily life aspects and to examine diferences of these aspects between 
adherent and non-adherent patients. Setting Two community pharmacies in the Netherlands. Method In this cross-sectional 
study patients (≥ 45 years) using cardiovascular medication participated. Two equally group sized samples of patients 
non-adherent as assessed with pharmacy reill data, and patients adherent were selected. Main outcome measure Data were 
collected by means of the Living with Medicines Questionnaire measuring the impact of medicines use on patients’ daily 
lives. Results In total, 196 patients participated, including 96 non-adherent patients. Substantial proportions of patients 
experienced medication-related burden on diferent daily life aspects. This burden was mainly related to the acceptance of 
long-term medicine use, medication-related concerns or dissatisfaction, the interference of medicines with social and daily 
lives, and the interaction and communication with health care providers. No statistically signiicant results were found when 
comparing the impact on patients’ daily lives between adherent and nonadherent patients. Conclusion Health care providers 
should acknowledge the impact of multiple long-term medicines on patient’s daily lives and should make an efort to dimin-
ish patients’ medication-related burden by improving patient–provider relationships and by providing adequate treatment 
information incorporating patients’ individual circumstances. This may facilitate the integration of long-term medicine use 
in patients’ daily lives.
Keywords Cardiovascular medication · Medication-related burden · Medication non-adherence · Patients’ daily lives · The 
Netherlands
Impacts on practice
• Multiple long-term medicines use affects different 
aspects of patients’ daily lives, and this impact needs to 
be recognized.
• Health care providers should consider this medication-
related burden on patients when managing chronic condi-
tions.
• Health care providers should make an efort to support 
patients to better integrate long-term medicine use in 
their daily and social lives.
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Introduction
Patients with chronic diseases are confronted with develop-
ing an understanding of the disease and treatment, should 
attend regular appointments, take several chronic medicines 
and enact lifestyle changes [1–5]. The management of chronic 
diseases therefore requires substantial personal investment 
from patients. Treatment regimens are complex and long-
term medicine use creates burden for patients [1]. A systematic 
review identiied ive dimensions of medication-related bur-
den: burden related to medication routines, medication charac-
teristics, adverse efects, health care system and social aspects 
[6]. Excessive medication-related burden may increase the 
negative impact on patients’ daily lives and negatively afects 
the health-related quality of life [7, 8]. This is especially the 
case in patients with cardiovascular disease for whom mostly 
multiple medicines are prescribed and for whom most medi-
cines prescribed must be used until the end of their life [1, 
2]. Patients who experience excessive medication-related bur-
den may encounter problems with adhering to the prescribed 
regimen [3, 6, 9, 10]. As a consequence, patients become 
non-adherent to their medication which in its turn leads to 
increased morbidity and mortality, more hospital admissions 
and higher health care costs [11, 12]. Limited data on patients’ 
experienced burden of long-term medicine use and its impact 
on patients’ daily lives especially in cardiovascular disease 
are available.
Aim of the study
The aim of the present study was to explore the impact of 
chronic cardiovascular medication use on diferent aspects of 
patients’ daily lives and to examine the diferences of these 
aspects between adherent and non-adherent patients.
Ethics approval
All procedures performed in studies involving human par-
ticipants were in accordance with the ethical standards of the 
institutional and/or national research committee and with the 
1964 Helsinki declaration and its later amendments or com-
parable ethical standards. The Medical Ethics Committee of 
the VU University Medical Center Amsterdam approved this 
study. Informed consent was obtained from all individual par-
ticipants included in this study.
Method
Study design
A cross-sectional study was performed in an urban area of 
the Netherlands. We intended to include two equally group-
sized samples of patients adherent and non-adherent to their 
prescribed cardiovascular medication. Two community phar-
macies participated. Data were collected by means of the 
Living with Medicines Questionnaire (LMQ-2) [13]. This 
is an easy-to-use and well-designed instrument to measure 
the impact of medicine use on patients’ daily lives. The 
questionnaire has originally been developed in the United 
Kingdom (UK) based on in-depth interview with patients 
prescribed four or more regular medicines to explore the 
issues associated with long-term medicine use [8, 13]. The 
questionnaire was sent by post to the home addresses of 
eligible patients.
Study population
Patients were eligible if they were 45 years or older and 
were prescribed cardiovascular medication including anti-
hypertensives, antihyperlipidemics and anticoagulants for 
more than 1 year. Exclusion criteria were patients who were 
unable to ill out a questionnaire, had insuicient Dutch lan-
guage skills or used repeat dispensing which is an addition-
ally ofered service by the pharmacy.
Selection procedure
Non‑adherent sample
The selection method of the Dutch Foundation for Phar-
maceutical Statistics (SFK) was used in order to identify 
non-adherent patients [14]. SFK has been developed by 
the Royal Dutch Pharmacists Association and collects 
information on dispensed drugs from the majority of the 
pharmacies in the Netherlands. Using this software, the 
Proportion of Days Covered (PDC) was calculated and a 
list of non-adherent patients (PDC < 80%) was assembled. 
In each pharmacy a random sample was taken from this 
list using a randomisation table. A limitation of the SFK 
method for the selection of non-adherent patients is that 
data concerning medication reill or medication regimen 
changes may sometimes be missing. As a result, patients 
can be falsely classiied as non-adherent. Therefore, each 
patient in the sample was contacted by telephone in order 
to verify whether the low PDC could be explained by the 
following factors: (1) visits to another pharmacy to reill 
medication, (2) hospital admissions, (3) a health care 
International Journal of Clinical Pharmacy 
1 3
provider initiated discontinuation or (4) changes to the 
prescribed regimen. Patients able to explain their reill 
non-adherence with one of the above described aspects in 
the previous period, were reclassiied to the adherent sam-
ple. Patients that denied these explanations, were included 
in the inal non-adherent sample.
Adherent sample
The pharmacy information and administration system was 
used to identify adherent patients by making a list of all 
patients in the pharmacy that met the inclusion criteria. 
Again a sample of these patients was taken using a ran-
domisation table. In order to only include adherent patients 
(PDC ≥ 80%), patients that were present on the SFK list as 
described above were subsequently excluded. The remain-
ing patients in the sample were contacted by telephone and 
asked for participation.
Data collection
LMQ-2 measures the impact of medicine use on patients’ 
daily lives and consists of 42 items divided over eight 
themes: (1) patient–doctor relationships and communica-
tion about medicines, (2) interferences with daily life, (3) 
practicalities, (4) efectiveness, (5) patient–pharmacist com-
munication about medicines, (6) acceptance of medicine use, 
(7) autonomy/control over medicine use and (8) concerns 
about potential harm. Responses are rated on a ive-point 
Likert scale to measure the extent of agreement with the 
42 items, ranging from 1 (strongly disagree) to 5 (strongly 
agree) [15]. The LMQ-2 has been shown to be a valid and 
reliable multidimensional measure of prescription medicine 
use experiences and was robust against potential obsequious-
ness bias [15].
In order to use the LMQ-2 in the Netherlands, the ques-
tionnaire was translated using a forward–backward proce-
dure in which the English version was irst translated into 
Dutch by the researchers. The Dutch version was thereaf-
ter translated backwards into English by a native speaker 
in order to verify the accordance with the original English 
version. The accordance with the English version was veri-
ied and approved by the developer of the questionnaire (JK). 
After the translation process, the feasibility and readability 
of the Dutch version of the questionnaire was tested in a 
sample (n = 10) of patients using chronic cardiovascular 
medication using the ‘think-aloud’ method. This method 
enables to identify diicult or unclear sentences, because 
patients read aloud every word in each question [16]. The 
questionnaire was not further adapted based upon the test 
results.
Data analysis
Patient characteristics including age, gender, origin, educa-
tion level, employment status, living situation, assistance 
with medication use from others and number of prescribed 
medicines were obtained. Means and standard deviations for 
continuous variables and frequencies and percentages for cat-
egorical variables were calculated. The 42 items were both 
positively and negatively phrased. Reverse scoring enabled 
uniformity in the direction of responses, with a higher score 
indicating more impact of medicines use on patients’ daily 
lives. The LMQ-2 sum score was obtained by summing the 
scores for each item and was presented as means and standard 
deviations. The sum score ranges from 42 to 210. In addi-
tion, a theme sum score was calculated for each of the eight 
themes. Independent samples t tests were used to compare 
sum and theme scores between the adherent and non-adherent 
sample. When examining the LMQ-2 scores on item level, 
the scale was dichotomised into 1 (strongly agree, agree with 
item) and 0 (strongly disagree, disagree, neutral with item) 
[17]. Proportions of patients agreeing with the LMQ-2 items 
were presented as frequencies and percentages for the total 
study population. Furthermore, logistic regression analyses 
were used in order to examine the diferences in LMQ-2 item 
scores between adherent and non-adherent patients. Odds 
ratios (OR) with 95% conidence intervals (CI) and p values 
were presented. A p value of ≤ 0.01 was considered statis-
tically signiicant. Statistical analyses were performed using 
SPSS version 22.0 (IBM Corp, Armonk, NY, USA).
Fig. 1  Flow diagram of study population




A total of 394 patients were invited to participate (Fig. 1). 
Of patients willing to participate (n = 295), 94 patients 
did not respond to the questionnaire and ive individu-
als were excluded due to missing questionnaire data. The 
inal sample consisted of 196 patients, including 100 and 
96 patients in the adherent and non-adherent sample, 
respectively.
Patient characteristics
In Table 1 the patient characteristics are listed. In the total 
study population the mean age was 71.0 years and 51.0% 
was male. Patients were predominantly from Dutch origin 
(89.8%), retired (65.8%) and lived with others (74.0%). 
About two-thirds of patients was prescribed at least four 
medicines. No signiicant diferences in patient character-
istics between the adherent and non-adherent sample were 
found, except for number of prescribed medicines. Sig-
niicantly more non-adherent patients used more than four 
prescribed medicines (p = 0.004) than adherent patients.
Impact of medicines use on daily life
In Table 2 the results of the LMQ-2 sum scores and themes 
scores are presented. In the total study population the mean 
sum score was 93.1 (SD 13.6). For the adherent and non-
adherent patients, the sum score was 93.2 (SD 13.3) and 93.0 
(SD 14.0), respectively. No statistically signiicant difer-
ences between the adherent and non-adherent patients were 
found for neither the LMQ-2 sum score nor LMQ-2 theme 
scores.
In Table 3 the results of the LMQ-2 scores on item level 
are presented. A selection of notable results on the propor-
tions of patients agreeing with the items are described below. 
In both the adherent and non-adherent sample almost a quar-
ter of patients indicated not to trust the doctor in choosing 
their medicines (24.0%) and almost half of the patients indi-
cated that their doctor does not always take their concerns of 
side efects seriously (42.3%). About 40% of patients indi-
cated they were concerned about experiencing side efects or 
Table 1  Characteristics of the 
study population
SD standard deviation
a Total exceeds 100%
b Data from ive patients is missing
c Signiicantly diferent between adherent and non-adherent patients (p = 0.004)
Patient characteristics Total study popula-
tion (N = 196)
Adherent sample (N = 100) Non-adherent sample (N = 96)
N (%) or mean ± SD N (%) or mean ± SD N (%) or mean ± SD
Age (years) 71.0 ± 10.6 71.4 ± 10.2 70.5 ± 11.0
Gender
Male 100 (51.0) 54 (54.0) 46 (47.9)
Origin
Dutch 176 (89.8) 93 (93.0) 83 (86.5)
Education
Low 47 (24.0) 21 (21.0) 26 (27.1)
Moderate 56 (28.6) 29 (29.0) 27 (28.1)
High 93 (47.4) 50 (50.0) 43 (44.8)
Employment statusa
Employed 53 (21.9) 23 (23.0) 20 (20.8)
Volunteer 15 (7.7) 7 (7.0) 8 (8.3)
Retired 129 (65.8) 66 (66.0) 63 (65.6)
Unemployed/disabled 19 (9.7) 9 (9.0) 10 (10.4)
Living situation
With others 145 (74.0) 75 (75.0) 70 (72.9)
Assistance with medication use
Yes 22 (11.2) 12 (12.0) 10 (10.4)
No. of prescribed medicinesb,c
≥ 4 133 (67.9) 59 (60.2) 74 (79.6)
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were concerned about long-term efects of taking medicines. 
For up to 35% of patients medicines adversely afected their 
social and daily lives, including not living their life as they 
want to (34.7%) and experiencing interference with their 
social life (23.0%). A majority of the patients indicated not 
to be able to adapt their medicine-taking to their lifestyles 
(57.7%). One out of four patients indicated they did not 
accept that they have to take medicines long term (23.0%). 
Over one-third of patients (35.2%) indicated not being con-
ident about speaking with the pharmacist about medicines.
When comparing the adherent and non-adherent patients, 
no statistically signiicant diferences between groups were 
found on LMQ-2 item level. For one item, ‘I ind using my 
medicines diicult’ (p = 0.012), the proportion of non-
adherent patients was marginally signiicantly higher than 
adherent patients. Other trends were that a lower proportion 
of non-adherent patients agreed with the statement: ‘My 
medicines allow me to live my life as I want to’ (p = 0.046), 
and a higher proportion with the statement: ‘I can change the 
times I take my medicines if I want to’ (p = 0.032).
Discussion
This study demonstrated that the experienced burden of 
cardiovascular medication use on patients’ daily lives was 
mainly related to the acceptance of long-term medicine use, 
medication-related concerns or dissatisfaction, the inter-
ference of medicines with social and daily lives, and the 
interaction and communication with health care providers. 
There were no signiicant diferences in experienced burden 
between the adherent and non-adherent sample.
In this study, substantial proportions of patients expe-
rienced medication-related burden. The majority of these 
indings resonate with the results of two other studies admin-
istrating the LMQ [17, 18]. These studies concluded that 
long-term use of medicines was burdensome and may nega-
tively afect patients’ quality of life. The inding of our study 
that the experienced medication-related burden was related 
to diferent daily life aspects, corresponds with other litera-
ture. In a review of Sav et al. [19] diferent dimensions of 
treatment burden were identiied in multiple studies includ-
ing side efects of treatment, the economic burden imposed 
by treatment, time required to obtain, administer and manage 
treatment, and the psychosocial aspects of burden includ-
ing the impact on social and daily lives. In contrast to this 
review, no conclusions can be drawn about the experienced 
economic burden in our study population since no costs 
related aspects were assessed in the questionnaire. In a 
review of Rosbach and Andersen [20] it was also concluded 
that the burden of treatment is a complex concept consist-
ing of many diferent components and factors interacting 
with each other. They also found that patients seem to use 
strategies to diminish the burden and try to routinize and 
integrate complex treatment into their daily lives. Since, the 
experienced medication-related burden is also related to the 
interaction with health care providers, a structural change in 
health care delivery is required to diminish patients’ burden 
[21]. Therefore, it is important for health care providers to 
recognise that poor patient–provider relationships may lead 
to increased burden and that they should make an efort to 
improve communication about patients’ attitudes and con-
cerns, involve patients in treatment decisions and incorpo-
rating individual’s circumstances and preferences [1, 4, 7]. 
This may increase the chance to better integrate long-term 
Table 2  LMQ-2 sum scores and theme scores of adherent and non-adherent patients
LMQ Living with Medicines Questionnaire, SD standard deviation









Sum score (range 42–210) 93.1 ± 13.6 93.2 ± 13.3 93.0 ± 14.0 0.931
Theme scores
1 Patient–doctor relationships and communication about medi-
cines (9–45)
19.8 ± 4.6 19.8 ± 4.0 19.8 ± 5.2 0.985
2 Interferences with daily life (8–40) 17.7 ± 4.4 17.7 ± 4.5 17.8 ± 4.3 0.909
3 Practicalities (7–35) 13.3 ± 3.7 13.3 ± 3.8 13.3 ± 3.6 0.989
4 Efectiveness (4–20) 8.9 ± 2.3 9.0 ± 2.2 8.9 ± 2.4 0.743
5 Patient–pharmacist communication about medicines (3–15) 6.2 ± 1.8 6.2 ± 1.7 6.2 ± 1.8 0.848
6 Acceptance of medicine use (4–20) 8.3 ± 2.7 8.3 ± 2.5 8.3 ± 2.9 0.960
7 Autonomy/control over medicine use (4–20) 12.8 ± 2.8 13.1 ± 2.9 12.5 ± 2.8 0.157
8 Concerns about potential harm (3–15) 8.4 ± 2.7 8.1 ± 2.8 8.6 ± 2.6 0.179
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Table 3  Diferences in proportions of patients agreeing with 42 LMQ items between adherent and non-adherent patients






Odds ratio (95% CI) p  valuea
Agree or strongly agree 
N (%)
Agree or strongly agree 
N (%)
Agree or strongly agree 
N (%)
Theme 1 Patient–doctor relationships and communication about medicines
My doctor(s) listens to my 
opinions and concerns 
about my medicines
142 (72.4) 74 (74.0) 68 (70.8) 0.85 (0.46–1.60) 0.620
The information my 
doctor(s) gives me about 
my medicines is useful
170 (86.7) 88 (88.0) 82 (85.4) 0.80 (0.35–1.83) 0.595
My doctor(s) spends 
enough time discussing 
my medicines with me
146 (74.5) 78 (78.0) 68 (70.8) 0.69 (0.36–1.31) 0.251
I am conident speaking to 
my doctor(s) about my 
medicines
145 (74.0) 76 (76.0) 69 (71.9) 0.81 (0.43–1.53) 0.511
My doctor(s) takes my 
concerns of side efects 
seriously
113 (57.7) 56 (56.0) 57 (59.4) 1.15 (0.65–2.03) 0.633
I understand what my 
doctor(s) tells me about 
my medicines
169 (86.2) 87 (87.0) 82 (85.4) 0.88 (0.39–1.97) 0.748
The health professionals 
providing my care know 
enough about me and my 
medicines
125 (63.8) 65 (65.0) 60 (62.5) 0.90 (0.50–1.61) 0.716
I trust the judgement of 
my doctor(s) in choosing 
medicines for me
149 (76.0) 74 (74.0) 75 (78.1) 1.26 (0.65–2.43) 0.499
There is enough sharing 
of information about 
my medicines between 
professionals providing 
my care
86 (43.9) 43 (43.0) 43 (44.8) 1.08 (0.61–1.89) 0.801
Theme 2 Interferences with daily life
Taking medicines inter-
feres with my social life
45 (23.0) 26 (26.0) 19 (19.8) 0.70 (0.36–1.38) 0.303
Taking medicines causes 
problems with daily 
tasks
17 (8.7) 6 (6.0) 11 (11.5) 2.03 (0.72–5.72) 0.182
The medicines I use have 
an adverse efect on the 
holidays I can take
8 (4.1) 6 (6.0) 2 (2.1) 0.33 (0.07–1.69) 0.185
My life revolves around 
using my medicines
55 (28.1) 27 (27.0) 28 (29.2) 1.11 (0.60–2.08) 0.736
Taking medicines afects 
my driving ability
8 (4.1) 5 (5.0) 3 (3.1) 0.61 (0.14–2.64) 0.511
I have to put a lot of plan-
ning and thought into 
taking my medicines
10 (5.1) 3 (3.0) 7 (7.3) 2.54 (0.634–0.14) 0.186
I worry that I have to take 
several medicines at the 
same time
16 (8.2) 8 (8.0) 8 (8.3) 1.05 (0.38–2.91) 0.932
Changes in daily routine 
cause problems with my 
medicines
41 (20.9) 23 (23.0) 18 (18.8) 0.77 (0.39–1.54) 0.465
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Table 3  (continued)






Odds ratio (95% CI) p  valuea
Agree or strongly agree 
N (%)
Agree or strongly agree 
N (%)
Agree or strongly agree 
N (%)
Theme 3 Practicalities
It is diicult to identify 
which medicine is which
20 (10.2) 11 (11.0) 9 (9.4) 0.84 (0.33–2.12) 0.707
The instructions on my 
medicines are easy to 
follow
187 (95.4) 94 (94.0) 93 (96.9) 1.98 (0.48–8.15) 0.345
I ind opening the packag-
ing of my medicines 
diicult
28 (14.3) 17 (17.0) 11 (11.5) 0.63 (0.28–1.43) 0.270
I ind getting my prescrip-
tions from the doctor 
diicult
14 (7.1) 6 (6.0) 8 (8.3) 1.42 (0.48–4.27) 0.528
I ind getting my medi-
cines from the pharma-
cist diicult
11 (5.6) 6 (6.0) 5 (5.2) 0.86 (0.25–2.92) 0.810
I ind using my medicines 
diicult
21 (10.7) 5 (5.0) 16 (16.7) 3.80 (1.33–10.83) 0.012*
It is easy to keep to my 
medicines routine
171 (87.2) 89 (89.0) 82 (85.4) 0.72 (0.31–1.68) 0.454
Theme 4 Effectiveness
I am satisied with the 
efectiveness of my 
medicines
131 (66.8) 67 (67.0) 64 (66.7) 0.99 (0.54–1.79) 0.960
My medicines live up to 
my expectations
131 (66.8) 67 (67.0) 64 (66.7) 0.99 (0.54–1.79) 0.960
My medicines are working 157 (80.1) 82 (82.0) 75 (78.1) 0.78 (0.39–1.58) 0.498
My medicines prevent my 
condition getting worse
126 (64.3) 60 (60.0) 66 (68.8) 1.47 (0.81–2.64) 0.202
Theme 5 Patient–pharmacist communication about medicines
The information my phar-
macist gives me about 
my medicines is useful
162 (82.7) 82 (82.0) 80 (83.3) 1.10 (0.52–2.30) 0.805
I am conident speaking to 
my pharmacist about my 
medicines
127 (64.8) 65 (65.0) 62 (64.6) 0.98 (0.55–1.77) 0.951
I understand what my 
pharmacist tells me 
about my medicines
166 (84.7) 81 (81.0) 85 (88.5) 1.81 (0.81–4.04) 0.146
Theme 6 Acceptance of medicine use
Taking medicines is rou-
tine for me
146 (74.5) 73 (73.0) 73 (76.0) 1.17 (0.62–2.24) 0.625
I accept that I have to take 
medicines long term
151 (77.0) 76 (76.0) 75 (78.1) 1.13 (0.58–2.20) 0.724
My medicines are impor-
tant to me
179 (91.3) 90 (90.0) 89 (92.7) 1.41 (0.52–3.88) 0.502
My medicines allow me to 
live my life as I want to
128 (65.3) 72 (72.0) 56 (58.3) 0.54 (0.30–0.99) 0.046*
Theme 7 Autonomy/control over medicine use
I can vary the dose of the 
medicines I take
19 (9.7) 9 (9.0) 10 (10.4) 1.18 (0.46–3.03) 0.738
I can change the times I 
take my medicines if I 
want to
101 (51.5) 44 (44.0) 57 (59.4) 1.86 (1.06–3.28) 0.032*
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treatment in patients’ daily lives. This inding was also con-
irmed by a review of Mohammed et al., which indicated 
a need for health care providers to have more insight into 
patients’ medication-related burden since it plays a central 
role in inluencing beliefs and behaviour towards medicines. 
By understanding patients’ experienced burden, health care 
providers can provide individualised care and assist patients 
in improving medication therapy and health outcomes [6].
No statistically signiicant results were found when com-
paring the burden on patients’ daily lives between the adher-
ent and non-adherent sample. The indings did not support 
our original hypothesis that non-adherent patients might per-
ceive more medication-related burden than adherent patients. 
The similar level of burden found between these two groups 
is therefore interesting and requires further exploration. 
The fact that the questionnaire was not able to distinguish 
between adherent and non-adherent patients can have several 
explanations. First, the perceived burden of chronic medica-
tion in adherent and non-adherent patients might be simi-
lar. Second, adherent and non-adherent patients may cope 
in a diferential manner with this burden. A questionnaire 
that is speciically designed to measure burden and not the 
coping mechanisms to manage this burden is not suitable 
to identify these diferences. In addition, rather than in the 
experienced burden, the beliefs about medicines might inlu-
ence medication intake behaviour [22, 23]. The marginal 
diferences between adherent and non-adherent patients in 
a few LMQ-2 items, including inding medicines use dii-
cult, feeling in control of changing times of medicine intake, 
and feeling that medicines allow living life as wanted, could 
be explained to support in this direction. However, these 
diferences should be viewed with caution due to multiple 
testing. It might be interesting to elaborate on the possible 
relationship of these items with non-adherence in further 
research.
Limitations
Some limitations need to be discussed. First, the accuracy 
of the selection method of SFK to identify non-adherent 
patients is limited. It may occur that certain data in SFK is 
missing whereupon it is possible to falsely classify patients 
as non-adherent. However, to minimise bias missing SFK 
data was verified with each patient and when needed a 
patient was reclassiied. Another limitation was that the 
sample size was maybe not large enough to ind diferences 
between adherent and non-adherent patients. A inal limita-
tion was that the adherent and non-adherent samples were 
slightly diferent on patient characteristics. The samples dif-
fered on the number of prescribed medicines. In the UK, 
LMQ-2 scores have been shown to be related to the number 
of prescribed medicines [15]. However, in our sample no 
signiicant correlation was found (data not shown), but again 
this may be due to insuicient sample size.
Conclusion
This study demonstrated that substantial proportions of 
patients using chronic cardiovascular medication expe-
rienced medication-related burden on diferent daily life 
aspects. Health care providers must acknowledge the impact 
Table 3  (continued)






Odds ratio (95% CI) p  valuea
Agree or strongly agree 
N (%)
Agree or strongly agree 
N (%)
Agree or strongly agree 
N (%)
I can choose whether or 
not to take my medicines
67 (34.2) 29 (29.0) 38 (39.6) 1.60 (0.89–2.91) 0.120
I can adapt my medicine-
taking to my lifestyle
83 (42.3) 43 (43.0) 40 (41.7) 0.95 (0.54–1.67) 0.856
Theme 8 Concerns about potential harm
I am concerned about 
experiencing side efects
79 (40.3) 34 (34.0) 45 (46.9) 1.71 (0.96–3.05) 0.067
I am concerned about 
possible damaging long-
term efects of taking 
medicines
78 (39.8) 36 (36.0) 42 (43.8) 1.38 (0.78–2.46) 0.286
I worry that my medicines 
may interact with each 
other
20 (10.2) 10 (10.0) 10 (10.4) 1.05 (0.42–2.64) 0.923
CI conidence interval, LMQ Living with Medicines Questionnaire
a Logistic regression analyses *p ≤ 0.05; **p ≤ 0.01 (= statistical signiicant)
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of multiple long-term medicine use on patients’ daily lives 
and should make an efort to diminish patients’ medication-
related burden. Therefore, patient–provider relationships 
and their communication need to be improved, incorporat-
ing patients’ individual circumstances and preferences in 
order to facilitate the integration of long-term medicine use 
in patients’ daily lives. We did not ind diferences in expe-
rienced burden between adherent and non-adherent patients. 
It shows that we might underestimate the burden in adherent 
patients, which is an interesting inding. Further research 
could explore this and the potential efects of intervention 
strategies aimed at coping mechanisms for medication-
related burden on patients’ medication adherence.
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